Vaccines 'on demand': Science fiction or a future reality

Expert Opinion on Drug Discovery

Volumn 10, Issue 2, 2015, Pages 101-106

  Ulmer, Jeffrey B ^a   Mansoura, Monique K ^a   Geall, Andrew J ^a  

^a Novartis Vaccines Inc ^*  (United States)

Author keywords

Pandemic; Rapid response; Synthetic; Vaccines

Indexed keywords

RNA VACCINE; MESSENGER RNA; RECOMBINANT VACCINE;

BIOINFORMATICS; BIOSURVEILLANCE; CONTACT EXAMINATION; DRUG SAFETY; HEALTH CARE NEED; HEALTH CARE PLANNING; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA VECTOR; TREATMENT RESPONSE; VACCINE PRODUCTION; DRUG DELIVERY SYSTEM; IMMUNOLOGY; PHARMACEUTICS; PROCEDURES; TRENDS;

DRUG DELIVERY SYSTEMS; HUMANS; RNA, MESSENGER; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SYNTHETIC;

EID: 84921508727     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.996128     Document Type: Review

References (26)

1. Available from: http://www.whitehouse.gov/the-press-office/remarks-presidentstate-union-address
2. Available from: http://www.phe.gov/Preparedness/mcm/enterprisereview/Pages/default.aspx
3. Deering RP, Kommareddy S, Ulmer JB, et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 2014;11(6):885-99
4. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol 2013;25(2):152-9
5. Abelin A, Colegate T, Gardner S, et al. Lessons from pandemic influenza A (H1N1): the research-based vaccine industry's perspective. Vaccine 2011;29(6):1135-8
6. Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science 2012;336(6088):1531-3
7. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012;8(1):45-58
8. Dormitzer PR, Suphaphiphat P, Gibson DG, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013;5(185):185ra68
9. Al-Tawfiq JA, Zumla A, Gautret P, et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014;14(10):992-1000
10. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-8
11. Kaslow DC. A potential disruptive technology in vaccine development: genebased vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 2004;98(10):593-601
12. Smerdou C, Liljestrom P. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther 1999;1(2):244-51
13. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 2012;109(36):14604-9
14. Brito LA, Chan M, Shaw CA, et al. A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines. Mol ther 2014;22(12):2118-29
15. Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emer Microbes Infect 2013;2:8
16. Bogers WM, Oostermeijer H, Mooij P, et al. Potent immune responses in rhesus macaques induced by non-viral delivery of a self-amplifying RNA vaccine expressing HIV-1 envelope with a cationic nanoemulsion. J Infect Dis 2014. [Epub ahead of print]
17. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012;51(34):8529-33
18. Pokrovskaya ID, Gurevich VV. In vitro transcription: preparative RNA yields in analytical scale reactions. Anal Biochem 1994;220(2):420-3
19. Kallen KJ, Thess A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2014;2(1):10-31
20. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov 2014;13(10):759-80
21. Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng 2012;109(6):1443-60
22. De Groot AS, Einck L, Moise L, et al. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? Hum Vaccin Immunother 2013;9(9):1877-84
23. Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposomeentrapped mRNA. Eur J Immunol 1993;23(7):1719-22
24. Zhou X, Berglund P, Rhodes G, et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994;12(16):1510-14
25. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
26. Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30(1):1-7